Impact of Tobacco Cessation on the Development of Bladder Cancer

Video

Vikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.

Vikram Narayan, MD, spoke with CancerNetwork® at the Society of Urologic Oncology 21st Annual Meeting regarding tobacco cessation and how patients are often unaware of its role in helping to prevent bladder cancer recurrence.

Transcription:

I think this is a very promising time. The only other thing that I always mention to all of my patients that I think is really important is tobacco cessation and the fact that many people don’t realize that smoking, including secondhand smoke, is often the single leading cause of bladder cancer. I think efforts to try and quit smoking and get support to do so are going to be really important. It’s great that we have a lot of emerging treatment options but working on a plan and getting support to quit smoking is among the most important things that an individual can do to prevent bladder cancer recurrence. There are a lot of options available, both through a patient’s primary care physician as well as their urologist, if that’s something they are interested in pursuing.

Recent Videos
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Related Content